Analyst Price Target is $231.67
▲ +513.52% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for MERCK Kommanditgesellschaft auf Aktien in the last 3 months. The average price target is $231.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 513.52% upside from the last price of $37.76.
Current Consensus is
The current consensus among 8 contributing investment analysts is to hold stock in MERCK Kommanditgesellschaft auf Aktien. This rating has held steady since October 2020, when it changed from a Buy consensus rating.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.